163 related articles for article (PubMed ID: 35999636)
1. A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma.
Wang Y; Xiao F; Zhao Y; Mao CX; Yu LL; Wang LY; Xiao Q; Liu R; Li X; McLeod HL; Hu BW; Huang YL; Lv QL; Xie XX; Huang WH; Zhang W; Guo CX; Li JG; Yin JY
Mol Cancer; 2022 Aug; 21(1):169. PubMed ID: 35999636
[TBL] [Abstract][Full Text] [Related]
2. A two-stage genome-wide association study identifies novel germline genetic variations in CACNA2D3 associated with radiotherapy response in nasopharyngeal carcinoma.
Yu LL; Hu BW; Huang HX; Yu B; Xiao Q; Lv QL; Luo CH; Guo CX; Li JG; Xie XX; Yin JY
J Transl Med; 2023 Jan; 21(1):11. PubMed ID: 36624463
[TBL] [Abstract][Full Text] [Related]
3. Genome-Wide Association Study of Susceptibility Loci for Radiation-Induced Brain Injury.
Wang TM; Shen GP; Chen MY; Zhang JB; Sun Y; He J; Xue WQ; Li XZ; Huang SY; Zheng XH; Zhang SD; Hu YZ; Qin HD; Bei JX; Ma J; Mu J; Yao Shugart Y; Jia WH
J Natl Cancer Inst; 2019 Jun; 111(6):620-628. PubMed ID: 30299488
[TBL] [Abstract][Full Text] [Related]
4. An extended genome-wide association study identifies novel susceptibility loci for nasopharyngeal carcinoma.
Cui Q; Feng QS; Mo HY; Sun J; Xia YF; Zhang H; Foo JN; Guo YM; Chen LZ; Li M; Liu WS; Xu M; Zhou G; He F; Yu X; Jia WH; Liu J; Zeng YX; Bei JX
Hum Mol Genet; 2016 Aug; 25(16):3626-3634. PubMed ID: 27436580
[TBL] [Abstract][Full Text] [Related]
5. The comparison of prognostic value of tumour volumetric regression ratio and RECIST 1.1 criteria after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
Zeng YY; Xiang ZZ; He T; Liu F; Shao BF; Yan RN; Ma JC; Wang XR; Liu L
Oral Oncol; 2020 Dec; 111():104924. PubMed ID: 32736209
[TBL] [Abstract][Full Text] [Related]
6. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ
Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417
[TBL] [Abstract][Full Text] [Related]
7. The detrimental effects of radiotherapy interruption on local control after concurrent chemoradiotherapy for advanced T-stage nasopharyngeal carcinoma: an observational, prospective analysis.
Yao JJ; Jin YN; Wang SY; Zhang F; Zhou GQ; Zhang WJ; Zhi-Bin ; Cheng ; Ma J; Qi ZY; Sun Y
BMC Cancer; 2018 Jul; 18(1):740. PubMed ID: 30012115
[TBL] [Abstract][Full Text] [Related]
8. Predictive Value of ERCC1 mRNA Level from Receiver-Operator Characteristic and Pretreatment EBV-DNA Virus Load in Stage II Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy with Concurrent Cisplatin.
Hua L; Chen S; Wei M; Shen Y; Long J; Lin Z; Meng Y; Guo C; Huang H; Tu X; Yao M
Cancer Biother Radiopharm; 2022 Feb; 37(1):2-10. PubMed ID: 33764811
[No Abstract] [Full Text] [Related]
9. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.
Lv X; Cao X; Xia WX; Liu KY; Qiang MY; Guo L; Qian CN; Cao KJ; Mo HY; Li XM; Li ZH; Han F; He YX; Liu YM; Wu SX; Bai YR; Ke LR; Qiu WZ; Liang H; Liu GY; Miao JJ; Li WZ; Lv SH; Chen X; Zhao C; Xiang YQ; Guo X
Lancet Oncol; 2021 May; 22(5):716-726. PubMed ID: 33857411
[TBL] [Abstract][Full Text] [Related]
10. X-chromosome association study reveals genetic susceptibility loci of nasopharyngeal carcinoma.
Zuo XY; Feng QS; Sun J; Wei PP; Chin YM; Guo YM; Xia YF; Li B; Xia XJ; Jia WH; Liu JJ; Khoo AS; Mushiroda T; Ng CC; Su WH; Zeng YX; Bei JX
Biol Sex Differ; 2019 Mar; 10(1):13. PubMed ID: 30909962
[TBL] [Abstract][Full Text] [Related]
11. Development of a Nomogram Model for Treatment of Nonmetastatic Nasopharyngeal Carcinoma.
Zhang LL; Xu F; Song D; Huang MY; Huang YS; Deng QL; Li YY; Shao JY
JAMA Netw Open; 2020 Dec; 3(12):e2029882. PubMed ID: 33306119
[TBL] [Abstract][Full Text] [Related]
12. High risk Epstein-Barr virus variants characterized by distinct polymorphisms in the EBER locus are strongly associated with nasopharyngeal carcinoma.
Hui KF; Chan TF; Yang W; Shen JJ; Lam KP; Kwok H; Sham PC; Tsao SW; Kwong DL; Lung ML; Chiang AKS
Int J Cancer; 2019 Jun; 144(12):3031-3042. PubMed ID: 30536939
[TBL] [Abstract][Full Text] [Related]
13. Multiplex Epstein-Barr virus BALF2 genotyping detects high-risk variants in plasma for population screening of nasopharyngeal carcinoma.
Miller JA; Sahoo MK; Yamamoto F; Huang C; Wang H; Zehnder JL; Le QT; Pinsky BA
Mol Cancer; 2022 Jul; 21(1):154. PubMed ID: 35902864
[TBL] [Abstract][Full Text] [Related]
14. Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma.
Lee AW; Ngan RK; Tung SY; Cheng A; Kwong DL; Lu TX; Chan AT; Chan LL; Yiu H; Ng WT; Wong F; Yuen KT; Yau S; Cheung FY; Chan OS; Choi H; Chappell R
Cancer; 2015 Apr; 121(8):1328-38. PubMed ID: 25529384
[TBL] [Abstract][Full Text] [Related]
15. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH
Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056
[TBL] [Abstract][Full Text] [Related]
16. A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity.
Lee AWM; Tung SY; Ng WT; Lee V; Ngan RKC; Choi HCW; Chan LLK; Siu LL; Ng AWY; Leung TW; Yiu HHY; O'Sullivan B; Chappell R
Cancer; 2017 Nov; 123(21):4147-4157. PubMed ID: 28662313
[TBL] [Abstract][Full Text] [Related]
17. A polygenic risk score for nasopharyngeal carcinoma shows potential for risk stratification and personalized screening.
He YQ; Wang TM; Ji M; Mai ZM; Tang M; Wang R; Zhou Y; Zheng Y; Xiao R; Yang D; Wu Z; Deng C; Zhang J; Xue W; Dong S; Zhan J; Cai Y; Li F; Wu B; Liao Y; Zhou T; Zheng M; Jia Y; Li D; Cao L; Yuan L; Zhang W; Luo L; Tong X; Wu Y; Li X; Zhang P; Zheng X; Zhang S; Hu Y; Qin W; Deng B; Liang X; Fan P; Feng Y; Song J; Xie SH; Chang ET; Zhang Z; Huang G; Xu M; Feng L; Jin G; Bei J; Cao S; Liu Q; Kozlakidis Z; Mai H; Sun Y; Ma J; Hu Z; Liu J; Lung ML; Adami HO; Shen H; Ye W; Lam TH; Zeng YX; Jia WH
Nat Commun; 2022 Apr; 13(1):1966. PubMed ID: 35414057
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era.
Li PJ; Mo HY; Luo DH; Hu WH; Jin T
Oral Oncol; 2018 Oct; 85():95-100. PubMed ID: 30220326
[TBL] [Abstract][Full Text] [Related]
19. How genome-wide SNP-SNP interactions relate to nasopharyngeal carcinoma susceptibility.
Su WH; Yao Shugart Y; Chang KP; Tsang NM; Tse KP; Chang YS
PLoS One; 2013; 8(12):e83034. PubMed ID: 24376627
[TBL] [Abstract][Full Text] [Related]
20. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
Wei Z; Zhang Z; Luo J; Li N; Peng X
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
